
OSC Edge Achieves Perfect Score on CMMC C3PAO Level 2 Assessment
'This perfect score is a testament to our team's expertise and commitment to securing our nation's most critical missions,' says Tiffany Bailey, CEO of OSC Edge.
Share
The flawless assessment validates OSC Edge's robust cybersecurity framework, built on secure-by-design systems engineering, NIST SP 800-171 and SP 800-53 governance, and advanced technical controls like endpoint protection, SIEM, and encrypted communications. This achievement positions OSC Edge as a trusted partner for DoD contractors navigating CMMC compliance.
'This perfect score is a testament to our team's expertise and commitment to securing our nation's most critical missions,' says Tiffany Bailey, CEO of OSC Edge. 'We're proud to set the standard for cybersecurity excellence and support our clients with unparalleled solutions.'
'This achievement reflects years of disciplined processes and a culture of security-first innovation,' adds Corey Ogletree, PMP, CISSP-ISSEP, ITIL, GCIH, Director of Information Technology and Cybersecurity at OSC Edge. 'Our team's work ensures DoD partners can trust us to deliver compliant, resilient IT environments.'
The assessment success highlights the collaborative efforts of OSC Edge's cybersecurity team, including Peter Shoars, Kenyatta Jabbar, Neel Patel, and Jatin Gohil, alongside strategic guidance from Lee Hendrickson, Jim Spencer, Skeeter Lieberum, Jina Hardy and Romain Nowakowski. Their work ensures OSC Edge's processes are repeatable, auditable, and aligned with DoD's highest standards.
As a mission-focused company, OSC Edge continues to drive innovation in cybersecurity, cloud, and infrastructure, supporting critical initiatives like the Air Force's Base Infrastructure Modernization (BIM) program.
About OSC Edge
OSC Edge is a wholly owned subsidiary of Cook Inlet Region, Inc. (CIRI), an Alaska Native Corporation proudly owned by over 9,400 Shareholders. CIRI is one of 12 land-based Alaska Native regional corporations created by the Alaska Native Claims Settlement Act (ANCSA) of 1971 and benefits Alaska Native people who had ties to the Cook Inlet region and beyond. Learn more at www.oscedge.com.
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
a day ago
- Yahoo
4 Words From Palantir CEO Alex Karp That BigBear.ai Investors Can't Ignore
Key Points Palantir has an established reputation for working closely with the U.S. military. is seeking to compete with Palantir in the world of artificial intelligence (AI) defense operations. Following second-quarter earnings from both companies earlier this month, the Department of Defense's (DOD) preferred vendor between Palantir and couldn't be any more clear. 10 stocks we like better than Palantir Technologies › Dr. Alex Karp isn't your typical corporate executive. He doesn't hold an MBA, and his public remarks often come in the form of unscripted, philosophical musings. Yet as CEO of data analytics powerhouse Palantir Technologies (NASDAQ: PLTR), Karp has led the company's transformation from a secretive government contractor into a leading force in artificial intelligence (AI) adoption across the enterprise software landscape. What many investors once viewed as a niche corridor, the intersection of defense operations and AI has swiftly become fertile ground supporting Palantir's generational run. The company has secured some of the Department of Defense's (DOD) most complex, mission-critical contracts, worth billions of dollars, cementing its role as a trusted partner in national security. Following Palantir's monster Q2 earnings report earlier this month, Karp's confidence was on full display. During an interview on financial news program CNBC, he delivered a blunt message to Palantir's rivals: "read 'em and weep." Let's unpack what Karp really meant and assess why investors in competing platforms such as (NYSE: BBAI) can no longer afford to ignore Palantir's commanding lead in the AI defense arena. Palantir is setting the pace to become the AI backbone for military operations During the second quarter, Palantir's revenue surged 48% year over year to $1.0 billion. While that growth is impressive on its own, the finer details reveal just how deeply Palantir has embedded itself in the military operations pocket of the AI landscape. The company's government segment grew 49% year over year, slightly outpacing overall growth. Drilling down further, Palantir's U.S. government revenue rose by an even stronger 53% -- reaching $426 million in the quarter. This momentum is supported by a string of high-profile Pentagon deals. In March, Palantir partnered with defense contractors Northrop Grumman and L3Harris Technologies, along with autonomous systems specialist Anduril, in a $178 million U.S. Army deal to help build the Tactical Intelligence Targeting Access Node (TITAN) ground transportation system. Just months later, the Army extended its relationship with Palantir, awarding a $795 million extension to continue using the company's Maven Smart System(MSS) platform -- bringing the total deal value above $1.2 billion. More recently, Palantir further strengthened its public sector footprint with two additional contracts: a multiyear contract with the Army worth up to $10 billion, as well as a separate award to help develop a surveillance system for Immigration and Customs Enforcement (ICE). Why is this important for investors? During second-quarter earnings call, CEO Kevin McAleenan acknowledged that the company has "seen disruptions in federal contracts from efficiency efforts this quarter, most notably in programs that support the U.S. Army, as they seek to consolidate and modernize their data architecture." Given the details outlined above, there's a strong possibility that the "disruptions" McAleenan referenced reflect Palantir winning these contracts. While operates in some of the same broad fields as Palantir, such as AI analytics and machine learning, I think the comparison between the two companies is increasingly lopsided. Each new government contract awarded to Palantir deepens its competitive moat. The company's Foundry and Gotham platforms are evolving into a comprehensive, integrated ecosystem for the public sector -- supporting a range of mission-critical needs. Rather than true "network effects," Palantir is enjoying a cumulative competitive edge that's compounding with each deployment of its software -- ultimately broadening the company's footprint, strengthening its relationships, and making the cost of switching to competing platforms more costly. These dynamics have effectively given Palantir a mini-monopoly on certain pockets of public sector deal flow, beyond the capacities of traditional defense contractors specializing in manufacturing hardware or equipment. Is stock a buy? Karp's soundbite wasn't just swagger, nor was it merely aimed at short-sellers who have been betting against Palantir for years. It was a direct shot at every competing platform. The 2025 stock chart reflecting Palantir and tells a very different story. Palantir has built steady momentum on the back of rising deal flow, translating directly into accelerating revenue and profitability. by contrast, has seen far more volatile price swings, with its moves often driven by hype and the hopeful narrative that it could one day become the "next Palantir." That outcome appears increasingly improbable. Each new government contract Palantir secures widens the gap between it and smaller rivals struggling to keep pace. For investors seeking exposure to AI's role in military operations, Palantir offers a proven track record over speculative counterparts such as whose traction remains more aspirational than tangible. Should you invest $1,000 in Palantir Technologies right now? Before you buy stock in Palantir Technologies, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the for investors to buy now… and Palantir Technologies wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $668,155!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $1,106,071!* Now, it's worth noting Stock Advisor's total average return is 1,070% — a market-crushing outperformance compared to 184% for the S&P 500. Don't miss out on the latest top 10 list, available when you join Stock Advisor. See the 10 stocks » *Stock Advisor returns as of August 13, 2025 Adam Spatacco has positions in Palantir Technologies. The Motley Fool has positions in and recommends L3Harris Technologies and Palantir Technologies. The Motley Fool has a disclosure policy. 4 Words From Palantir CEO Alex Karp That Investors Can't Ignore was originally published by The Motley Fool


Business Wire
2 days ago
- Business Wire
Tivic Health Advances Discussions on Use of Entolimod as a Radiation Countermeasure at Military Health System Research Symposium 2025
FREMONT, Calif.--(BUSINESS WIRE)--Tivic Health® Systems, Inc. (Nasdaq: TIVC), a diversified therapeutics company, is proud to announce it advanced discussions with key US Government agencies through its participation in the 2025 Military Health System Research Symposium (MHSRS), held August 4-7, 2025, in Kissimmee, Florida. The MHSRS is the Department of Defense's premier scientific meeting that brings together military, academic, and industry experts to discuss medical research and innovation in support of warfighter health and readiness. Direct Access to DoD Decision-Makers and Researchers MHSRS provides direct access to organizations seeking military partnerships and connects companies with key funding organizations. Tivic's President of Biopharma and Chief Operating Officer, Michael Handley, met with key members of the Biomedical Advanced Research and Development Authority (BARDA), the Armed Forces Radiobiology Research Institute (AFRRI) and the Medical CBRN Defense Consortium (MCDC) to discuss potential pathways to deploy Entolimod as a military countermeasure. BARDA's mission is to develop medical countermeasures that address the public health and medical consequences of chemical, biological, radiological, and nuclear (CBRN) accidents, incidents and attacks, pandemic influenza, and emerging infectious diseases. AFRRI's mission is to defend the Nation from nuclear and radiological threats through research, leadership, training, and education. The MCDC was formed in response to the US Government's expressed interest to engage and fund advanced development efforts to support the Department of Defense's (DoD) medical pharmaceutical and diagnostic requirements as related to enhancing the mission effectiveness of military personnel. 'It was an honor to contribute to the vital conversations that were focused generally on radiation medical countermeasures, and specifically on our lead clinical product candidate, Entolimod, which has the potential to protect the warfighter in the instance that they are exposed to radiation,' said Handley. Representatives from Tivic joined global thought leaders, military leaders and researchers to share insights, explore collaborative opportunities, and present ongoing research intended to improve health outcomes for warfighters exposed to radiation in the field. About MHSRS MHSRS serves as a dynamic platform for the exchange of research findings across multiple disciplines, including combat casualty care, medical countermeasures, infectious disease, and mental health. The symposium fosters collaboration among business leaders, scientists, clinicians, and policymakers, ensuring innovations reach those who serve as quickly and effectively as possible. About Tivic Tivic's dual platform utilizes the body's biopharmaceutical and bioelectronic systems to treat unmet medical needs through targeting the immune system. Tivic's biologics compounds activate an innate immune pathway to prevent cell death in the bone marrow and epithelial tissues across systems impacted by radiation and age. The company's lead drug candidate, Entolimod™ for acute radiation syndrome, is a novel TLR5 agonist that has been granted Fast Track designation and is in late stage development. Tivic's bioelectronic program is developing a novel, non-invasive medical device designed to target the neural pathways implicated in many prevalent and debilitating diseases. Early trials show promising signals that Tivic's approach may regulate specific biologic responses, and the company believes its early-stage vagus nerve stimulation device has the potential to deliver clinical outcomes similar to or better than those of surgically implanted devices. To learn more about Tivic, visit: Forward-Looking Statements This press release may contain 'forward-looking statements' that are subject to substantial risks and uncertainties. All statements, other than statements of historical fact, contained in this press release are forward-looking statements. Forward-looking statements contained in this press release may be identified by the use of words such as 'anticipate,' 'believe,' 'contemplate,' 'could,' 'estimate,' 'expect,' 'intend,' 'seek,' 'may,' 'might,' 'plan,' 'potential,' 'predict,' 'project,' 'target,' 'aim,' 'should,' 'will' 'would,' or the negative of these words or other similar expressions, although not all forward-looking statements contain these words. Forward-looking statements are based on Tivic Health Systems Inc.'s current expectations and are subject to inherent uncertainties, risks, and assumptions that are difficult to predict. Further, certain forward-looking statements are based on assumptions as to future events that may not prove to be accurate, including as a result of interactions with and guidance from the FDA and other regulatory authorities, as well as interactions with governmental agencies, such as BARDA, the AFRRI and the MCDC; changes to the company's relationship with the its partners; the failure to obtain FDA or similar clearances or approvals and noncompliance with FDA or similar regulations; the company's future development of its ncVNS treatment, Entolimod and Entolasta; changes to the company's business strategy; timing and success of clinical trials and study results; regulatory requirements and pathways for approval; consummation of any strategic transactions; the company's need for, and ability to secure when needed, additional working capital; the company's ability to maintain its Nasdaq listing; and changes in tariffs, inflation, legal, regulatory, political and economic risks. Actual results could differ materially from those contained in any forward-looking statement as a result of various factors. Accordingly, you are cautioned not to place undue reliance on such forward-looking statements. For a discussion of risks and uncertainties relevant to the company, and other important factors, see Tivic Health's filings with the SEC, including, its Annual Report on Form 10-K for the year ended December 31, 2024, filed with the SEC on March 21, 2025, under the heading 'Risk Factors," as well as the company's subsequent filings with the SEC. Forward-looking statements contained in this press release are made as of this date, and Tivic Health Systems, Inc. undertakes no duty to update such information except as required by applicable law.
Yahoo
3 days ago
- Yahoo
BigBear.ai Holdings Shares Plunge. Is This a Buying Opportunity or a Red Flag?
Key Points badly missed revenue expectations in Q2. The company now expects to report its lowest-ever yearly revenue as a public company. It does not show the characteristics of an AI software company. 10 stocks we like better than › Share prices of (NYSE: BBAI) plunged earlier this week after the analytics and systems integrator badly missed revenue and earnings expectations when it reported its second-quarter results. However, the stock is still trading up more than 300% over the past year, as of this writing. The shares initially staged a big rally in early February after the company announced a contract win with the Department of Defense's (DoD) Chief Digital and Artificial Intelligence Office to design a Virtual Anticipation Network (VANE) prototype. This platform will use artificial intelligence (AI) models to analyze news media coming from potential U.S. adversaries. After a pullback following this strong early-year run, the stock rallied again to start the summer. A combination of overall strong AI sentiment, along with a few notable announcements -- such as a new strategic partnership in the United Arab Emirates and its participation in Project Convergence-Capstone 5 (PC-C5) -- helped power the stock ahead. Let's take a closer look to see if the drop could be a buying opportunity, or if it's a warning to stay away. A big revenue miss for In Q2, badly missed revenue expectations, as revenue sank 18% year over year to $32.5 million. That missed the $40.6 million analyst consensus, as compiled by S&P Global Market Intelligence. The company blamed the miss on the federal government's efforts to reduce costs, saying that this disrupted contracts it has with the United States Army, which has been working to modernize its data architecture. Note, however, that this doesn't appear to have affected Palantir Technologies, which reported great results and recently signed a $10 billion, 10-year contract with the U.S. Army that consolidated 75 contracts into a single contract. said it "welcomes" this type of disruption, as it will lead to the Army using more software solutions to solve mission-critical problems. However, CEO Kevin McAleenan admitted that the company relies on too few large contracts and needs to broaden its customer base and the market it serves. How much of a true software company actually is, though, is questionable, as can be seen in its low gross margins. In the quarter, its gross margin fell to 25% from 27.8% a year ago. Those are just not software or AI gross margins. Because the company's engineers and data scientists must co-locate and be on-premises for many of its government projects, it has structurally low gross margins. Gross margins are important, as the higher they are, the easier it is to turn revenue into profits. In comparison, Palantir had a gross margin of nearly 81% in Q2. On the profitability front, adjusted EBITDA (earnings before interest, taxes, depreciation, and amortization) was a loss of $8.7 million, compared to a loss of $3.7 million a year ago. The decline came from lower revenue, reduced gross margin, and higher research and development expenses. The company continued to burn cash in the quarter, but it took advantage of its high stock price to sell shares and solidify its balance sheet. It generated cash flow from operations of negative $3.9 million in the quarter and negative $7.1 million in the first half. However, after raising $293.4 million in proceeds from at-the-market (ATM) stock sales, it ended the quarter with $390.8 million in cash and equivalents and $103.1 million in debt. Looking ahead, reduced its full-year revenue forecast to be between $125 million and $140 million, down from a prior outlook of $160 million to $180 million. That would be a decline from the $158.2 million in revenue the company saw in 2024. Should investors buy the dip or stay away? is simply not a software company riding the AI wave. It doesn't have the gross margins or predictable revenue stream of a software-as-a-service (SaaS) company. It also hasn't seen a big revenue lift from AI. In fact, its revenue this year is set to come in at the lowest level ever since the stock debuted in December 2021 through a SPAC. While the stock has staged a big rally this year, its share count is also up nearly 50% in the past year. That's massive dilution. The company has done nothing to deserve the big rally it's seen over the past year, and I think the sell-off in the stock was actually pretty tame given its results and guidance. While some investors may want to hope that can turn into the next Palantir, that is just highly unlikely. I think a lot more downside could be in store, and as such, I'd stay far away. Do the experts think is a buy right now? The Motley Fool's expert analyst team, drawing on years of investing experience and deep analysis of thousands of stocks, leverages our proprietary Moneyball AI investing database to uncover top opportunities. They've just revealed their to buy now — did make the list? When our Stock Advisor analyst team has a stock recommendation, it can pay to listen. After all, Stock Advisor's total average return is up 1,062% vs. just 185% for the S&P — that is beating the market by 877.34%!* Imagine if you were a Stock Advisor member when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $649,544!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $1,113,059!* The 10 stocks that made the cut could produce monster returns in the coming years. Don't miss out on the latest top 10 list, available when you join Stock Advisor. See the 10 stocks » *Stock Advisor returns as of August 13, 2025 Geoffrey Seiler has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends Palantir Technologies and S&P Global. The Motley Fool has a disclosure policy. Holdings Shares Plunge. Is This a Buying Opportunity or a Red Flag? was originally published by The Motley Fool Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data